Surgery plus endocrine therapy showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) probably leads to lower overall survival (OS) compared with no PMRT (moderate certainty).
The review found no eligible studies for this question.
Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).
Surgery showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).